Thrombogenesis, atherogenesis and angiogenesis in vascular disease: A new 'vascular triad'

Annals of Medicine

Volumn 36, Issue 2, 2004, Pages 119-125

  Lip, Gregory Y H ^a   Blann, Andrew D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis; Atherogenesis; Thrombogenesis; Vascular disease

Indexed keywords

BLOOD CLOTTING FACTOR 7; VASCULOTROPIN;

ANGIOGENESIS; ATHEROGENESIS; ATHEROMA; ATHEROMATOSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CELL DAMAGE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER METASTASIS; MELANOMA CELL; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOGENESIS; TUMOR GROWTH; VASCULAR DISEASE; VEIN THROMBOSIS;

ARTERIOSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOSIS;

EID: 1942440941     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310021607     Document Type: Review

References (58)

1. Virchow R. Gesammalte abhandlungen zur wissenschaftlichen medtzin. Frankfurt: Medinger Sohn & Co; 1856:219-732.
2. Blann AD, Lip GYH. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res 2001;101:321-7.
3. Ross R. Atherosclerosis - An inflammatory disease. New Engl J Med 1999;340:115-26.
4. Barer AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: Vasa vasorum and neovascularisation of human coronary arteries. New Engl J Med 1984;310:175-7.
5. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB, et al. Angiogenesis in human coronary artery plaques. Am J Pathol 1994;145:883-94.
6. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vase Med 1998;3:231-9.
7. Loscalzo J. The relationship between atherosclerosis and thrombosis. Circulation 1992;86 (suppl. III):95-9.
8. Boissel J-P, Chesebro JH. Atherothrombosis: a unifying concept. Eur Heart J 1999;1 (Suppl A):A1-44.
9. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JC for the ECAT group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. New Engl J Med 1995;332:635-41.
10. Smith FB, Lee AJ, Hau CM, Rumley A, Lowe GDO, Fowkes FGR. Plasma fibrinogen, haemostatic factors and prediction of peripheral arterial disease in the Edinburgh artery study. Blood Coagul Fibrinolysis 2000;11:43-50.
11. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiber L. Increased platelet and coagulatory activity-indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996;82:523-43.
12. Kamath S, Lip GYH. Fibrinogen: biochemistry, epidemiology and determinants. QJM 2003;96:711-29.
13. Mutin M, Canavy , Blann AD, Bory M, Sampol J, Dignat-George F. Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 1999;93:2951-8.
14. Blann AD. Viewpoint: Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis 2000;11:623-30.
15. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998;91:3527-61.
16. Salven P, Mustjoki S, Alitalo R, Alitalo K, Raffi S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003;101:168-72.
17. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komstsu R, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions. Circulation 1998;98:2108-16.
18. Couffinhal T, Kearney M, Witzenbichler B, Chen D, Murohara T, Losordo DW, et al. Vascular endothelial growth factor/vascular permeability factor (VEF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 1997;150:1673-85.
19. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GYH. Vascular endothelial growth factor and its receptor Flt-1 in the plasma of patients with coronary and peripheral atherosclerosis and type II diabetes. Clin Sci (Lond) 2002;102:187-94.
20. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
21. Battegay E. Angiogenesis: mechanistic insight, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-46.
22. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth, microvascular hyperpermeability, and angiogenesis. Am J Path 1995;146:1029-39.
23. Zhang HT, Craft P, Scott PAE, Ziehe M, Weich HA, Harris AL. et al. Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995;87:213-9.
24. Belgore F, Neil D, Blann AD, Ahmed AS, Lip GYH. Localisation of vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol 2003 in press.
25. Ferrara N. Winer J, Burton T. Aortic smooth muscle cells express and secrete vascular endothelial growth factor. Growth Factors 1991;5:141-8.
26. Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK, et al. Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000;6:166-71.
27. Seto S, Onodera H, Kaido T, Yoshikawa A, Ishigami S, Arii S, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301.
28. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663-8.
29. Mechtcheriakova D, Wlachos A, Holzmuller H, Binder BR, Hofer E. VEGF-induced TF expression in endothelial cells in mediated by EGR-1. Blood 1999;93:3811-23.
30. Camera M, Giesen PL, Fallon J, Aufiero BM, Taubman M, Tremoli E, et al. Cooperation between VEGF and TNF alpha is necessary for exposure of active TF on the surface of human endothelial cells. Arterioscl Thromb Vasc Biol 1999;19:531-7.
31. Lip GYH, Chin BSP, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002;3:27-34.
32. Nemerson Y. Tissue factor: Then and now. Thromb Haemost 1995;7:180-4.
33. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998;79:495-9.
34. Blann AD, Amiral J, McCollum CN, Lip GYH. Differences in free and total tissue factor pathway inhibitor, and rissue factor in peripheral artery disease compared to controls. Atherosclerosis 2000;152:29-34.
35. Chung NAY, Belgore F, LI-Saw-Hee FL, Conway DSG, Blann AD, Lip GYH. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor? Stroke 2002;33:2187-91.
36. Makin AJ, Chung NA, Silverman SH, Lip GYH. Vascular endothelial growth factor and tissue factor in patients with established peripheral artery disease: a link between angiogenesis and thrombogenesis? Clin Sci (Lond) 2003;104:397-404.
37. Donnelly R, Yeung JMC. Therapeutic angiogenesis: a step forward in intermittent claudication. Lancet 2002;359:2048-50.
38. Battegay EJ. Angiogenesis: mechanistic insight, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-46.
39. Eisenstein R. Angiogenesis in arteries: Review. Pharmacol Ther 1991;49:1-19.
40. Schultz A, Lavie L, Hochberg I, Beyar R, Stone T, Skorecki K, et al. Inter-individual heterogeneity in the hypoxia regulation of VEGF: significance for development of coronary attety collateral circulation. Circulation 1999;100:547-52.
41. Kamat BR, Galli SJ, Barer AC, Lainey LL, Sliverman KJ. Neovascularisation and coronary atherosclerotic plaque: Cinematographic localisation and quantitative histological analysis. Human Pathol 1987;18:1036-42.
42. Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularisation. Arterioscl Thromb Vase Biol 2000;20:2573-8.
43. El-Gendi H, Violaris AG, Foale R, Sharma HS, Sheridan DJ. Endogenous, local, vascular endothelial growth factor production in patients with chronic total coronary artery occlusions: further evidence for its role in angiogenesis. Heart 2002;87:158-9.
44. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF 165 in patient with ischaemic limb. Lancet 1996;348:370-4.
45. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
46. Alber HF, Dulak J, Frick M, Dichtl W, Schwarzacher SP, Pachinger O, et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 2002;39:1951-5.
47. Blann AD, Belgore FM, Constans J, Conri C, Lip GYH. Vascular endothelial growth factor and its receptor, Fit-1, in the plasma of patients with hyperlipidaemia and atherosclerosis and the effect of lipid lowering therapy. Am J Cardiol 2001;87:1160-3.
48. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GYH. Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol 2001;87:805-7.
49. Jang JJ, Ho KYV, Kwan HH, Fajardo LF, Cooke JP. Angiogenesis is impaired by hypercholesterolaemia. Circulation 2000;102:1414-9.
50. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolaemic animals. Nat Med 2000;8:1004-10.
51. Hiang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 Prostate cells and CHRF megakaryocytes. Thromb Haemost 2001;86:1094-8.
52. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956-64.
53. Malamitsi-Puchner A, Sarandakou A, Tziotis J, Dafogianni C, Bartsocas C. Serum levels of basic fibroblast growth factor and vascular endothelial growth factor in children and adolescents with type 1 diabetes mellitus. Pediatric Res 1998;44:873-5.
54. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
55. Roldán V, Marín F, Lip GYH, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors: A review of the literature. Thromb Haemost 2003 in press.
56. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;376:517-9.
57. Vale PR, Isner JM, Rosenfield K. Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 2001;14:511-28.
58. Yang B, Cross DF, Ollerenshaw M, Millward BA, Demaine AG. Polymorphisms of the vascular endothelial growth factor and susceptibility to diabetic microvascular complications in patients with type 1 diabetes mellitus. J Diabetes Complications 2003;17:1-6.